Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Carbo/cyclo|DRUG: Carbo/cyclo + atezolizumab|DRUG: Paclitaxel|DRUG: Paclitaxel + Atezolizumab
Sponsor: The Netherlands Cancer Institute
Collaborators: Borstkanker Onderzoek Groep|Roche Pharma AG